Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07612631 · ClinicalTrials.gov registry record · Early Phase 1
Imaging CRF X NOP Interactions in Alcohol Use Disorder
A Early Phase 1 study, sponsored by Rajesh Narendran.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 90
- Enrollment target
NCT07612631: Recruiting Early Phase 1 study, sponsored by Rajesh Narendran.
NCT07612631 is a Early Phase 1 study that is actively recruiting participants, run by Rajesh Narendran. The registered enrollment target is 90 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07612631, a Early Phase 1 study, is actively recruiting participants, sponsored by Rajesh Narendran.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This positron emission tomography imaging study uses \[C-11\]NOP-1A and hydrocortisone to image stress-modulating proteins in heavy drinking alcohol use disorder (AUD) subjects and healthy controls (HC). It will also characterize the role of these stress-regulating proteins in a relapse to alcohol.
Primary Outcome
VT is the volume of distribution expressed relative to total plasma radioligand concentration; DELTA VT is the change from baseline to post-hydrocortisone
Interventions
- DRUG Hydrocortisone
- RADIATION Baseline [C-11]NOP-1A PET scan
- RADIATION Post-hydrocortisone [C-11]NOP-1A PET scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2032-06-30 |
| Phase | Early Phase 1 |
What NCT07612631 shows while recruiting
NCT07612631 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% higher).
The record links to 0 conditions, and to 3 interventions - of which Hydrocortisone is the first listed.
NCT07612631 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07612631 about?
NCT07612631 is a clinical study titled "Imaging CRF X NOP Interactions in Alcohol Use Disorder". This positron emission tomography imaging study uses \[C-11\]NOP-1A and hydrocortisone to image stress-modulating proteins in heavy drinking alcohol use disorder (AUD) subjects and healthy controls (HC). It will also characterize the role of these stress-regulating proteins in a relapse to alcohol.
What is the current status of trial NCT07612631?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 90 participants. The study started on 2026-06-01. Estimated completion is 2032-06-30.
What interventions are being tested in trial NCT07612631?
The interventions under investigation include: Hydrocortisone (DRUG), Baseline [C-11]NOP-1A PET scan (RADIATION), Post-hydrocortisone [C-11]NOP-1A PET scan (RADIATION).
Who is sponsoring clinical trial NCT07612631?
This trial is sponsored by Rajesh Narendran, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07612631's enrollment target sits among peer trials
90 233rd of 2000 higher than 1,753 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI